{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:22:36Z","timestamp":1792300956079,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.mce.2008.06.006","type":"journal-article","created":{"date-parts":[[2008,6,23]],"date-time":"2008-06-23T16:17:41Z","timestamp":1214237861000},"page":"237-243","source":"Crossref","is-referenced-by-count":90,"title":["Sartan\u2013AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism"],"prefix":"10.1016","volume":"302","author":[{"given":"I.","family":"Van Liefde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vauquelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2008.06.006_bib1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00894-005-0049-z","article-title":"Model of the whole rat AT1 receptor and the ligand-binding site","volume":"12","author":"Baleanu-Gogonea","year":"2006","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.mce.2008.06.006_bib2","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1074\/jbc.272.7.4245","article-title":"The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII","volume":"272","author":"Balmforth","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2008.06.006_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000020505","article-title":"Mechanical stretch\/relaxation stimulates a cellular renin-angiotensin system in cultured rat mesangial cells","volume":"6","author":"Becker","year":"1998","journal-title":"Exp. Nephrol."},{"key":"10.1016\/j.mce.2008.06.006_bib4","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1021\/jm049024x","article-title":"Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1\/AT2 angiotensin II receptor antagonists","volume":"48","author":"Berellini","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2008.06.006_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1161\/01.HYP.0000119190.06968.f1","article-title":"Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice","volume":"43","author":"Campbell","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2008.06.006_bib6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1476-5381.1993.tb13877.x","article-title":"Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1 receptor subtype","volume":"110","author":"Criscione","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0014-2999(96)00794-7","article-title":"In vitro pharmacological characterization of a new selective angiotensin AT1 receptor antagonist, UR-7280","volume":"318","author":"De Arriba","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International Union of Pharmacology. XXIII. The Angiotensin II Receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.mce.2008.06.006_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1476-5381.1994.tb16191.x","article-title":"BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174","volume":"113","author":"Dickinson","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-2999(99)00205-8","article-title":"Insurmountable angiotensin II AT1 receptor antagonists: the role of tight antagonist binding","volume":"372","author":"Fierens","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0014-2999(98)00965-0","article-title":"Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected Chinese hamster ovary cells","volume":"367","author":"Fierens","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3317\/jraas.2000.044","article-title":"Lys199 Mutation of the human angiotensin II AT1 receptor differently affects the binding of surmountable and insurmountable non-peptide antagonists","volume":"1","author":"Fierens","year":"2000","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"10.1016\/j.mce.2008.06.006_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0006-2952(02)00859-6","article-title":"Distinct binding properties of the AT1 receptor antagonist [3H]candesartan to intact cells and membrane preparations","volume":"63","author":"Fierens","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.bone.2003.07.010","article-title":"Connective tissue growth factor mRNA expression pattern in cartilages is associated with their type I collagen expression","volume":"33","author":"Fukunaga","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.mce.2008.06.006_bib15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1210\/er.21.1.90","article-title":"Uncovering molecular mechanisms involved in activation of G protein-coupled receptors","volume":"21","author":"Gether","year":"2000","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2008.06.006_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0014-5793(03)01404-2","article-title":"Agonist induction, conformational selection, and mutant receptors","volume":"556","author":"Giraldo","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.mce.2008.06.006_bib17","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1074\/jbc.272.3.1822","article-title":"Mutation of Asn111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation","volume":"272","author":"Groblewski","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2008.06.006_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0014-2999(98)00016-8","article-title":"Endothelin ET(B) receptors show different binding profiles in intact cells and cell membrane preparations","volume":"345","author":"Hara","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib19","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1161\/01.CIR.97.19.1952","article-title":"Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice","volume":"97","author":"Harada","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.mce.2008.06.006_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0014-2999(99)00297-6","article-title":"The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm","volume":"375","author":"Hulme","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0165-6147(02)00050-0","article-title":"Agonist induction and conformational selection during activation of a G-protein-coupled receptor","volume":"24","author":"Hunyady","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.mce.2008.06.006_bib22","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/HYPERTENSIONAHA.106.080994","article-title":"Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin","volume":"49","author":"Iekushi","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2008.06.006_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0031-6997(25)06948-0","article-title":"The classification of seven transmembrane receptors in recombinant expression systems","volume":"48","author":"Kenakin","year":"1996","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.mce.2008.06.006_bib24","doi-asserted-by":"crossref","first-page":"24037","DOI":"10.1074\/jbc.273.37.24037","article-title":"Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice","volume":"273","author":"Kudoh","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2008.06.006_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.yjmcc.2007.05.012","article-title":"Stretch-induced MAP kinase activation in cardiac myocytes: differential regulation through beta1-integrin and focal adhesion kinase","volume":"43","author":"Lal","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.mce.2008.06.006_bib26","doi-asserted-by":"crossref","first-page":"23107","DOI":"10.1074\/jbc.C200201200","article-title":"Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N- and C-terminal amino acid residues of angiotensin II in human AT1 receptor activation","volume":"277","author":"Le","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2008.06.006_bib27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0006-2952(03)00072-8","article-title":"Peptide and non-peptide antagonist interaction with constitutively active human AT1 receptors","volume":"65","author":"Le","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.bjp.0707323","article-title":"Angiotensin II AT1 antagonism and insurmountability: comparison of olmesartan and telmisartan","volume":"151","author":"Le","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1476-5381.1986.tb10239.x","article-title":"Peripheral 5-HT2-like receptors. Can they be classified with the available antagonists?","volume":"88","author":"Leff","year":"1986","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib30","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1124\/jpet.107.124958","article-title":"Neurokinin (NK)1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy","volume":"322","author":"Lindstr\u00f6m","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.mce.2008.06.006_bib31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1124\/mol.64.6.1271","article-title":"Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective","volume":"64","author":"Milligan","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib32","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1291\/hypres.26.937","article-title":"Molecular analysis of the structure and function of the angiotensin II type 1 receptor","volume":"26","author":"Miura","year":"2003","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.mce.2008.06.006_bib33","doi-asserted-by":"crossref","first-page":"19288","DOI":"10.1074\/jbc.M602144200","article-title":"Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor","volume":"281","author":"Miura","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2008.06.006_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/me.2007-0312","article-title":"Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state","volume":"22","author":"Miura","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.mce.2008.06.006_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00005344-199501000-00005","article-title":"Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist","volume":"25","author":"Mochizuki","year":"1995","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib36","doi-asserted-by":"crossref","first-page":"C1155","DOI":"10.1152\/ajpcell.2000.279.4.C1155","article-title":"Cyclic stretch activates p38 SAPK2-, ErbB2-, and AT1-dependent signalling in bladder smooth muscle cells","volume":"279","author":"Nguyen","year":"2000","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.mce.2008.06.006_bib37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-2952(93)90420-2","article-title":"Inhibition of rabbit aoritc angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist","volume":"46","author":"Noda","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib38","doi-asserted-by":"crossref","first-page":"28511","DOI":"10.1074\/jbc.270.48.28511","article-title":"Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation","volume":"270","author":"Noda","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2008.06.006_bib39","doi-asserted-by":"crossref","first-page":"16435","DOI":"10.1021\/bi961593m","article-title":"The active state of the AT1 angiotensin receptor is generated by angiotensin II induction","volume":"35","author":"Noda","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.mce.2008.06.006_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14779072.1.1.51","article-title":"The role of renin\u2013angiotensin\u2013aldosterone system inhibition in chronic kidney disease","volume":"1","author":"Norris","year":"2003","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.mce.2008.06.006_bib41","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1016\/S0895-7061(99)00250-2","article-title":"Newly emerging pharmacologic differences in angiotensin II receptor blockers","volume":"13","author":"Oparil","year":"2000","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.mce.2008.06.006_bib42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2006.10.001","article-title":"Type 1 angiotensin receptor pharmacology: signalling beyond G proteins","volume":"113","author":"Oro","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.mce.2008.06.006_bib43","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.bcp.2008.03.001","article-title":"Antagonist-dopamine D2L-receptor interactions in intact cells","volume":"75","author":"Packeu","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib44","doi-asserted-by":"crossref","first-page":"C1247","DOI":"10.1152\/ajpcell.1998.275.5.C1247","article-title":"Stretch activates heparin-binding EGF-like growth factor expression in bladder smooth muscle cells","volume":"275","author":"Park","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.mce.2008.06.006_bib45","doi-asserted-by":"crossref","first-page":"7615","DOI":"10.1073\/pnas.110142297","article-title":"Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay","volume":"97","author":"Parnot","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mce.2008.06.006_bib46","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/0092-8674(93)90541-W","article-title":"Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro","volume":"75","author":"Sadoshima","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.mce.2008.06.006_bib47","doi-asserted-by":"crossref","first-page":"H2898","DOI":"10.1152\/ajpheart.00546.2006","article-title":"Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes","volume":"292","author":"Saygili","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.mce.2008.06.006_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1476-5381.1994.tb16899.x","article-title":"Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists","volume":"113","author":"Schambye","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib49","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/jm0204237","article-title":"Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites","volume":"46","author":"Schmidt","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2008.06.006_bib50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1291\/hypres.22.147","article-title":"Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics","volume":"22","author":"Timmermans","year":"1999","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.mce.2008.06.006_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0008-6363(99)00057-7","article-title":"Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II","volume":"43","author":"van Kesteren","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.mce.2008.06.006_bib52","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0006-2952(99)00403-7","article-title":"Reversible and syntopic interaction between angiotensin II AT1 receptor antagonists and human AT1 receptors expressed in CHO-K1 cells","volume":"59","author":"Vanderheyden","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3317\/jraas.2000.020","article-title":"Binding characteristics of [3H]irbesartan to human recombinant angiotensin II type 1 receptors","volume":"1","author":"Vanderheyden","year":"2000","journal-title":"J. Renin\u2013Angiotensin\u2013Aldosterone Syst."},{"key":"10.1016\/j.mce.2008.06.006_bib54","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bjp.0702398","article-title":"Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors","volume":"126","author":"Vanderheyden","year":"1999","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib55","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuint.2007.05.005","article-title":"Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation","volume":"51","author":"Vauquelin","year":"2007","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.mce.2008.06.006_bib56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1472-8206.2005.00319.x","article-title":"G protein-coupled receptors: a count of 1001 conformations","volume":"19","author":"Vauquelin","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib57","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.tips.2006.05.001","article-title":"From slow antagonist dissociation to long- lasting receptor protection","volume":"27","author":"Vauquelin","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.mce.2008.06.006_bib58","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1177\/14703203010020010401","article-title":"Distinctions between non-peptide angiotensin II AT1 receptor antagonists","volume":"2","author":"Vauquelin","year":"2001","journal-title":"J. Renin\u2013Angiotensin\u2013Aldosterone Syst."},{"key":"10.1016\/j.mce.2008.06.006_bib59","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0006-2952(00)00546-3","article-title":"A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists","volume":"61","author":"Vauquelin","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib60","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0165-6147(00)01739-9","article-title":"Insurmountable AT(1) receptor antagonism: the need for different antagonist binding states of the receptor","volume":"22","author":"Vauquelin","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.mce.2008.06.006_bib61","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1177\/14703203010020010501","article-title":"Role of basic amino acids of the human angiotensin type1 receptor in the binding of the non-peptide antagonist candesartan","volume":"2","author":"Vauquelin","year":"2001","journal-title":"J. Renin\u2013Angiotensin\u2013Aldosterone Syst."},{"key":"10.1016\/j.mce.2008.06.006_bib62","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0165-6147(02)02081-3","article-title":"Models and methods for studying insurmountable antagonism","volume":"23","author":"Vauquelin","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.mce.2008.06.006_bib63","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.hjh.0000220403.61493.18","article-title":"Long-lasting AT1 receptor binding and protection by candesartan: comparison to other biphenyl-tetrazole sartans","volume":"24","author":"Vauquelin","year":"2006","journal-title":"J. Hypertens."},{"key":"10.1016\/j.mce.2008.06.006_bib64","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1472-8206.2000.tb00443.x","article-title":"Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors","volume":"14","author":"Verheijen","year":"2000","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib65","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bcp.2004.01.004","article-title":"Effect of saponin and filipin on antagonist binding to AT1 receptors in intact cells","volume":"67","author":"Verheijen","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib66","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0026-895X(25)09255-7","article-title":"Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies","volume":"41","author":"Wienen","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1476-5381.1993.tb13800.x","article-title":"Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277","volume":"110","author":"Wienen","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mce.2008.06.006_bib68","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/01.RES.77.2.258","article-title":"Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy","volume":"77","author":"Yamazaki","year":"1995","journal-title":"Circ. Res."},{"key":"10.1016\/j.mce.2008.06.006_bib69","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1172\/JCI118054","article-title":"Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes","volume":"96","author":"Yamazaki","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mce.2008.06.006_bib70","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ncb1137","article-title":"Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II","volume":"6","author":"Zou","year":"2004","journal-title":"Nat. Cell Biol."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720708002748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720708002748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:44:20Z","timestamp":1738269860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720708002748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0303720708002748"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2008.06.006","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}